ArticleScientific reports2026
Aptamer-linked immobilized sorbent assay for detection of VP1 of foot and mouth disease virus serotype O.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Foot and Mouth Disease (FMD) is one of the most devastating animal diseases. Infected animals, such as swine, develop vesicles, often leading to morbidity or depopulation of exposed herds. Current FMD diagnosis relies on serologic and immuno-based methods, which commonly encounter cross-reactivity and cost issues. Therefore, a simple and portable diagnostic tool would greatly aid its detection efforts. This study generated a novel aptamer sequence targeting viral protein 1 (VP1) of serotype O FMD virus (FMDV) by Systematic Evolution of Ligands by Exponential Enrichment (SELEX). The generated FMDV VP1-specific aptamer sequence was characterized and incorporated into an Aptamer-linked Immobilized Sorbent Assay (ALISA)-based microplate platform to detect FMDV VP1. Results showed that the aptamer, FMDV Apt, had an estimated dissociation constant (Kd) of 14 ± 8.6 nM, showing strong affinity for VP1 of FMDV. A concentration-dependent linear relationship (R2 = 0.9354) within a concentration range of 0.50 ng/mL – 5.0 ng/mL of FMDV VP1 protein was observed. The limit of detection (LOD) was determined to be 1.3 ng/mL, and the limit of quantification (LOQ) was approximately 4 ng/mL. Moreover, the FMD ALISA did not exhibit cross-reactivity when tested with high concentrations (500 ng/mL – 2,000 ng/mL) of non-targets, indicating its robustness and potential application in other detection platforms. The newly developed screening tool would facilitate efficient and inexpensive monitoring of potential biohazard risks posed by FMDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.